Exhibit 10.7
SECOND AMENDMENT TO LICENSE AGREEMENT
This Second Amendment to the License Agreement dated June 22, 2000 is made as of the 10 th day of June, 2002 by and between the University of Florida Research Foundation, Inc. ("UFRF"), a nonstock, nonprofit Florida corporation, and Oragenics, Inc. (formerly OraGen, Inc.) ("Licensee"), a corporation organized and existing under the laws of Florida.
WHEREAS, UFRF and Licensee (collectively "the Parties") entered into a License Agreement covering certain Licensed Patents, made effective June 22, 2000, and first amended on September 15, 2000; and
WHEREAS, the Parties have agreed to amend certain terms of the License Agreement, as amended;
NOW THEREFORE, in consideration of the mutual covenants and agreement set forth below, the Parties hereby amend Appendix A of the License Agreement as follows:
| Activity |
Completion Date |
|
|
|
|
Complete pre-clinical studies, including animal |
July 1, 2003 |
|
|
|
|
Submit IND to the FDA |
September 1, 2003 |
|
|
|
|
Complete Phase 1 Clinical Studies |
May 1, 2004 |
|
|
|
|
Complete Phase 2 and 3 Clinical Studies |
October 1, 2005 |
|
|
|
|
Submit NDA (as new antibiotic with specific claims) |
March 1, 2006 |
|
|
|
|
Receive FDA approval to market |
May 1, 2007 |
|
|
|
|
First commercial sale |
November 1, 2007 |
|
|
|
The License Agreement, as amended, except as further amended herein, shall remain in full force and effect and is hereby ratified and confirmed.
IN WITNESS WHEREOF, the Parties hereto have duly executed this Second Amendment to the License Agreement on the dates indicated below.
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
|||
|
|
|||
|
|
|||
|
BY: |
/s/ David L. Day |
Date: |
June ___, 2002 |
|
|
David L. Day |
|
|
|
|
|||
|
ORAGENICS, INC. |
|||
|
|
|||
|
|
|||
|
By: |
/s/ Mento A. Soponis |
Date: |
June ___, 2002 |
|
|
Mento A. Soponis |
|
|
|
|
|||
UFRF Ref: UF #1712
UF #10216
-2-